126378-73-2

Usage

Uses

Used in Pharmaceutical Research and Development:
Benzyl 3,4-dihydro-4-oxo-2-phenylpyridine-1(2H)-carboxylate is used as a compound with potential therapeutic applications for its promising bioactivity in various studies. Its structural features make it an interesting target for medicinal chemistry research, contributing to drug discovery and development.
Used in Drug Discovery:
Benzyl 3,4-dihydro-4-oxo-2-phenylpyridine-1(2H)-carboxylate is used as a compound of interest in the field of drug discovery due to its potential pharmacological properties and its role in pharmaceutical research and development.

Upstream product

• 620-08-6 4-methoxypyridine 
• 501-53-1 benzyl chloroformate 
• 100-58-3 phenylmagnesium bromide 

Downstream Products

• 335266-05-2 4-oxo-2-phenyl-pyridine-1-carboxylic acid benzyl ester 
• 334940-85-1 5-iodo-4-oxo-2-phenyl-3,4-dihydro-2H-pyridine-1-carboxylic acid benzyl ester 
• 414910-00-2 2-(4-fluoro-2-methyl-phenyl)-4-oxo-piperidine-1-carboxylic acid benzyl ester 

Relevant academic research and scientific papers

THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF

The invention provides a compound of formula: or a salt thereof, wherein the variables RAA, n, ring A, ring B, R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and R9 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

Synthesis of C2-symmetric trans-2,6-diarylpiperidinones via aryl cuprate addition: an unexpected stereochemical outcome

An efficient procedure for the preparation of trans-2,6-diaryl piperidinones has been developed. Addition of aryl Grignard reagents to 2-aryl dihydropyridones under catalytic copper promoted conditions generates the trans isomer exclusively, an unprecedented stereochemical event. The X-ray structures of both starting material and product have been solved and shed light on the steric constraints and substrate geometry leading to the observed product. The reaction conditions tolerate a variety of aromatic nucleophiles to generate C2-symmetric products in good overall yields.

NK1 ANTAGONIST

The invention is to a compound exhibiting neurokinin inhibitory properties, a pharmaceutical composition comprising same and a method of treatment for neurokinin-meditated conditions.Formula (I)

NOVEL PIPERIDINE COMPOUND

The present invention provides a novel piperidine compound of the formula [I]: wherein Ring A represents an optionally substituted benzene ring, Ring B represents an optionally substituted benzene ring, R1 represents an optionally substituted alkyl group, an optionally substituted hydroxyl group, etc., or a group of the formula: (a) wherein R11 and R12 are the same or different, and each represents hydrogen atom, a substituted carbonyl group, a substituted sulfonyl group, an optionally substituted alkyl group, etc., R2 represents hydrogen atom, etc., Z represents oxygen atom or a group represented by -N(R3)-, R3 represents hydrogen atom or an alkyl group, etc., R4 represents hydrogen atom or an alkyl group, etc.,or a pharmaceutically acceptable salt thereof.

Conversion of N-Acyl-2,3-dihydro-4-pyridones to 4-Chloro-1,2-dihydropyridines Using the Vilsmeier Reagent. Synthesis of (-)-Coniine and (+/-)-Lupinine

The full details are given of a study on the conversion of dihydropyridones of the type 3 to 4-chloro-1,2-dihydropyridines 4 using a Vilsmeier reagent.The use of 1 equiv of Vilsmeier reagent under mild conditions (ClCHCCl2, rt) transformed several racemic